A Phase 2a, 24-Week, Multi-Center, Open-Label Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Latest Information Update: 17 May 2021
At a glance
- Drugs SM 04646 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biosplice Therapeutics
- 02 Oct 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 13 Nov 2016 New trial record
- 01 Nov 2016 According to a Samumed media release, company is planning to launch this trial in 2016.